Literature DB >> 22494995

Cribriform-morular variant of papillary thyroid carcinoma in an 8-year-old girl: a case report with immunohistochemical and molecular testing.

Esther Diana Rossi1, Luca Revelli, Maurizio Martini, Alessandra Taddei, Claudio Pintus, Claudio Panunzi, Guido Fadda.   

Abstract

The description of the histological features and the immunohistochemical and molecular analyses of a case of cribriform-morular variant of papillary thyroid carcinoma in an 8-year-old girl with a family history of adenomatous polyposis is presented. The neoplasm was multifocal and bilateral, with a mixed pattern of solid, trabecular, and morular areas. The neoplasm showed angioinvasive behavior, extracapsular infiltration with extension to the perythyroidal muscles, and lymph node metastases. Tumor cells were positive for CAM 5.2, cytokeratins 5/6, TTF-1, HBME-1, galectin-3, and β-catenin. In addition, the molecular tests did not reveal BRAF mutations, RET/PTC rearrangement, APC mutation, or KRAS mutation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22494995     DOI: 10.1177/1066896912441830

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  2 in total

1.  Thyroid Carcinomas That Occur in Familial Adenomatous Polyposis Patients Recurrently Harbor Somatic Variants in APC, BRAF, and KTM2D.

Authors:  Taina T Nieminen; Christopher J Walker; Alisa Olkinuora; Luke K Genutis; Margaret O'Malley; Paul E Wakely; Lisa LaGuardia; Laura Koskenvuo; Johanna Arola; Anna H Lepistö; Pamela Brock; Ayse Selen Yilmaz; Ann-Kathrin Eisfeld; James M Church; Päivi Peltomäki; Albert de la Chapelle
Journal:  Thyroid       Date:  2020-03       Impact factor: 6.568

2.  TERT Promoter Mutation in an Aggressive Cribriform Morular Variant of Papillary Thyroid Carcinoma.

Authors:  Eun Ji Oh; Sohee Lee; Ja Seong Bae; Yourha Kim; Sora Jeon; Chan Kwon Jung
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.